311 related articles for article (PubMed ID: 25810260)
1. PPARα inhibition modulates multiple reprogrammed metabolic pathways in kidney cancer and attenuates tumor growth.
Abu Aboud O; Donohoe D; Bultman S; Fitch M; Riiff T; Hellerstein M; Weiss RH
Am J Physiol Cell Physiol; 2015 Jun; 308(11):C890-8. PubMed ID: 25810260
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of PPARα induces cell cycle arrest and apoptosis, and synergizes with glycolysis inhibition in kidney cancer cells.
Abu Aboud O; Wettersten HI; Weiss RH
PLoS One; 2013; 8(8):e71115. PubMed ID: 23951092
[TBL] [Abstract][Full Text] [Related]
3. Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth.
Wettersten HI; Landesman Y; Friedlander S; Shacham S; Kauffman M; Weiss RH
PLoS One; 2014; 9(12):e113867. PubMed ID: 25461627
[TBL] [Abstract][Full Text] [Related]
4. Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARα-independent mechanisms.
Yamasaki D; Kawabe N; Nakamura H; Tachibana K; Ishimoto K; Tanaka T; Aburatani H; Sakai J; Hamakubo T; Kodama T; Doi T
Eur J Cell Biol; 2011 Aug; 90(8):657-64. PubMed ID: 21514001
[TBL] [Abstract][Full Text] [Related]
5. Proteasome inhibition disrupts the metabolism of fumarate hydratase- deficient tumors by downregulating p62 and c-Myc.
Sourbier C; Ricketts CJ; Liao PJ; Matsumoto S; Wei D; Lang M; Railkar R; Yang Y; Wei MH; Agarwal P; Krishna M; Mitchell JB; Trepel JB; Neckers L; Linehan WM
Sci Rep; 2019 Dec; 9(1):18409. PubMed ID: 31804603
[TBL] [Abstract][Full Text] [Related]
6. Depletion of the triggering receptor expressed on myeloid cells 2 inhibits progression of renal cell carcinoma via regulating related protein expression and PTEN-PI3K/Akt pathway.
Zhang H; Sheng L; Tao J; Chen R; Li Y; Sun Z; Qian W
Int J Oncol; 2016 Dec; 49(6):2498-2506. PubMed ID: 27779645
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of c-FLIPL expression by miRNA-708 increases the sensitivity of renal cancer cells to anti-cancer drugs.
Kim EA; Kim SW; Nam J; Sung EG; Song IH; Kim JY; Kwon TK; Lee TJ
Oncotarget; 2016 May; 7(22):31832-46. PubMed ID: 27092874
[TBL] [Abstract][Full Text] [Related]
8. BRDT is a novel regulator of eIF4EBP1 in renal cell carcinoma.
Wan P; Chen Z; Zhong W; Jiang H; Huang Z; Peng D; He Q; Chen N
Oncol Rep; 2020 Dec; 44(6):2475-2486. PubMed ID: 33125143
[TBL] [Abstract][Full Text] [Related]
9. Upregulation of MARCKS in kidney cancer and its potential as a therapeutic target.
Chen CH; Fong LWR; Yu E; Wu R; Trott JF; Weiss RH
Oncogene; 2017 Jun; 36(25):3588-3598. PubMed ID: 28166200
[TBL] [Abstract][Full Text] [Related]
10. BML-111 Attenuates Renal Ischemia/Reperfusion Injury Via Peroxisome Proliferator-Activated Receptor-α-Regulated Heme Oxygenase-1.
Wu SH; Chen XQ; Lü J; Wang MJ
Inflammation; 2016 Apr; 39(2):611-24. PubMed ID: 26597893
[TBL] [Abstract][Full Text] [Related]
11. Effects of PPARα inhibition in head and neck paraganglioma cells.
Florio R; De Lellis L; di Giacomo V; Di Marcantonio MC; Cristiano L; Basile M; Verginelli F; Verzilli D; Ammazzalorso A; Prasad SC; Cataldi A; Sanna M; Cimini A; Mariani-Costantini R; Mincione G; Cama A
PLoS One; 2017; 12(6):e0178995. PubMed ID: 28594934
[TBL] [Abstract][Full Text] [Related]
12. Retinoic acid and the histone deacetylase inhibitor trichostatin a inhibit the proliferation of human renal cell carcinoma in a xenograft tumor model.
Touma SE; Goldberg JS; Moench P; Guo X; Tickoo SK; Gudas LJ; Nanus DM
Clin Cancer Res; 2005 May; 11(9):3558-66. PubMed ID: 15867260
[TBL] [Abstract][Full Text] [Related]
13. PTPN13 acts as a tumor suppressor in clear cell renal cell carcinoma by inactivating Akt signaling.
Long Q; Sun J; Lv J; Liang Y; Li H; Li X
Exp Cell Res; 2020 Nov; 396(1):112286. PubMed ID: 32919955
[TBL] [Abstract][Full Text] [Related]
14. Cafestol overcomes ABT-737 resistance in Mcl-1-overexpressed renal carcinoma Caki cells through downregulation of Mcl-1 expression and upregulation of Bim expression.
Woo SM; Min KJ; Seo BR; Nam JO; Choi KS; Yoo YH; Kwon TK
Cell Death Dis; 2014 Nov; 5(11):e1514. PubMed ID: 25375379
[TBL] [Abstract][Full Text] [Related]
15. Down-Regulation of Circular RNA_000926 Attenuates Renal Cell Carcinoma Progression through miRNA-411-Dependent CDH2 Inhibition.
Zhang D; Yang XJ; Luo QD; Fu DL; Li ZL; Zhang P; Chong T
Am J Pathol; 2019 Dec; 189(12):2469-2486. PubMed ID: 31476285
[TBL] [Abstract][Full Text] [Related]
16. Gramicidin A induces metabolic dysfunction and energy depletion leading to cell death in renal cell carcinoma cells.
David JM; Owens TA; Barwe SP; Rajasekaran AK
Mol Cancer Ther; 2013 Nov; 12(11):2296-307. PubMed ID: 24006494
[TBL] [Abstract][Full Text] [Related]
17. Knockdown of ALPK2 blocks development and progression of renal cell carcinoma.
Jiang J; Han P; Qian J; Zhang S; Wang S; Cao Q; Shao P
Exp Cell Res; 2020 Jul; 392(2):112029. PubMed ID: 32330508
[TBL] [Abstract][Full Text] [Related]
18. Fenofibrate down-regulates renal OCT2-mediated organic cation transport via PPARα-independent pathways.
Asavapanumas N; Kittayaruksakul S; Meetam P; Muanprasat C; Chatsudthipong V; Soodvilai S
Drug Metab Pharmacokinet; 2012; 27(5):513-9. PubMed ID: 22473497
[TBL] [Abstract][Full Text] [Related]
19. Dual and Specific Inhibition of NAMPT and PAK4 By KPT-9274 Decreases Kidney Cancer Growth.
Abu Aboud O; Chen CH; Senapedis W; Baloglu E; Argueta C; Weiss RH
Mol Cancer Ther; 2016 Sep; 15(9):2119-29. PubMed ID: 27390344
[TBL] [Abstract][Full Text] [Related]
20. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]